EAGLE ASSET MANAGEMENT INC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.

Quarter-by-quarter ownership
EAGLE ASSET MANAGEMENT INC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q4 2021$3,864,000
-78.7%
265,607
-31.3%
0.02%
-79.3%
Q3 2021$18,125,000
-41.2%
386,716
-23.6%
0.08%
-37.9%
Q2 2021$30,842,000
-0.8%
505,949
-3.4%
0.13%
-4.3%
Q1 2021$31,086,000
+26.3%
523,693
+51.4%
0.14%
-0.7%
Q4 2020$24,604,000346,0000.14%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q1 2022
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders